ArticleCurrent cardiology reviews2009
Thiazolidinediones and cardiovascular risk - a question of balance.
Article in Current cardiology reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.Drug design, development and therapy · 2021Trial
- Narrative Review "Dual Frontiers in Neurodegeneration: Pharmacological Synergies and Divergences in Parkinson's Disease and Type 2 Diabetes Mellitus".Cellular and molecular neurobiology · 2026Review
- Review
- Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.Advances in therapy · 2022Article
- Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease.Frontiers in cardiovascular medicine · 2020Review
- Shared and distinct mechanisms of fibrosis.Nature reviews. Rheumatology · 2019Review
- PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells.Journal of cellular and molecular medicine · 2019Article
- Phellopterin isolated fromHeliyon · 2018Article
- Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer.World journal of gastroenterology · 2014Review
- Diabetic cardiomyopathy: bench to bedside.Heart failure clinics · 2012Review
- The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.Nature reviews. Cancer · 2012Review
- Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization?British journal of pharmacology · 2011Review
- Can the electrophysiological action of rosiglitazone explain its cardiac side effects?Current medicinal chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral recent meta-analyses of adverse event data from randomized controlled trials with rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial events. This has led to debate on the overall clinical benefit of glitazone therapy for type 2 diabetes. Pioglitazone, on the other hand, has the most extensive cardiovascular outcomes database of all current glucose-lowering therapies, including a large prospective randomized controlled trial designed specifically to assess cardiovascular outcomes (PROactive). The available data suggest that pioglitazone is associated with a reduction in macrovascular risk.
aimsIn this review, we highlight some of the key factors that need to be considered when assessing the net clinical benefit of thiazolidinediones, focussing on both class effects and those specific to either rosiglitazone or pioglitazone.
resultsFor pioglitazone there appears to be no increase in the risk of overall macrovascular events and no adverse clinical consequences of developing signs of heart failure. Furthermore, there is good evidence of significant benefit regarding the composite of death, MI or stroke.
conclusionThe benefits seen with pioglitazone appear to outweigh the risks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.